Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Deciphera Pharmaceuticals, Inc. (DCPH)

15.45   0.43 (2.86%) 03-31 16:00
Open: 15.1 Pre. Close: 15.02
High: 15.46 Low: 14.95
Volume: 490,777 Market Cap: 1,173(M)

Technical analysis

as of: 2023-03-31 4:17:57 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 19     One year: 20.66
Support: Support1: 13.98    Support2: 11.63
Resistance: Resistance1: 16.27    Resistance2: 17.69
Pivot: 15.54
Moving Average: MA(5): 15.18     MA(20): 15.34
MA(100): 16.29     MA(250): 14.97
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 33.3     %D(3): 32.2
RSI: RSI(14): 50.4
52-week: High: 22.76  Low: 9.01
Average Vol(K): 3-Month: 840 (K)  10-Days: 556 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ DCPH ] has closed above bottom band by 46.4%. Bollinger Bands are 24.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 15.64 - 15.72 15.72 - 15.78
Low: 14.66 - 14.74 14.74 - 14.8
Close: 14.89 - 15.03 15.03 - 15.13

Company Description

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Headline News

Wed, 29 Mar 2023
Deciphera Pharmaceuticals, Inc.(DCPH) Investor Presentation ... - Seeking Alpha

Thu, 23 Mar 2023
Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 7% Since Last ... - Nasdaq

Thu, 23 Mar 2023
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Sold by ... - MarketBeat

Mon, 20 Mar 2023
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Given ... - MarketBeat

Fri, 17 Mar 2023
Deciphera Pharmaceuticals (DCPH) Investor Presentation ... - Seeking Alpha

Wed, 15 Mar 2023
Is Deciphera Pharmaceuticals Inc (DCPH) a Stock to Watch After Gaining 14.93% This Week? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 76 (M)
Shares Float 48 (M)
% Held by Insiders 29.9 (%)
% Held by Institutions 70.1 (%)
Shares Short 5,370 (K)
Shares Short P.Month 4,990 (K)

Stock Financials

EPS -2.28
EPS Est Next Qtl 0
EPS Est This Year -2.5
EPS Est Next Year -2.25
Book Value (p.s.) 5.05
Profit Margin (%) -133.5
Operating Margin (%) -136.4
Return on Assets (ttm) -25.9
Return on Equity (ttm) -55.4
Qtrly Rev. Growth 50.2
Gross Profit (p.s.) -0.83
Sales Per Share 1.76
EBITDA (p.s.) -2.37
Qtrly Earnings Growth 0
Operating Cash Flow -153 (M)
Levered Free Cash Flow -86 (M)

Stock Valuations

PE Ratio -6.78
PEG Ratio -0.4
Price to Book value 3.05
Price to Sales 8.75
Price to Cash Flow -7.68

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.